Hypothesis: In aged bone marrow, adipocyte-derived leptin activates the leptin receptor on erythroid progenitors, triggering JAK2-STAT3 signaling and upregulating SOCS3, which then blocks EPO-induced JAK2-STAT5 phosphorylation despite normal EPOR expression. This creates a functional EPO resistance that worsens anemia. Moreover, EPO-stimulated osteoclast activity raises RANKL and inflammatory cytokines (TNF-α, IL-6) that further stimulate adipocyte leptin production, forming a feed-forward loop that deepens the block.

It's known that aged marrow accumulates adipocytes, but the leptin-SOCS3 axis linking fat to erythroid signaling hasn't been directly tested.

Predictions

• Aged mice will show higher leptin receptor phosphorylation and SOCS3 protein in Ter119+CD71+ erythroid progenitors compared with young mice, and these levels will correlate positively with marrow adipocyte area and negatively with ex vivo EPO-stimulated pSTAT5.
• Conditional deletion of SOCS3 specifically in erythroid progenitors (using Gata1-Cre or EpoR-Cre) will restore EPO-induced pSTAT5, increase hemoglobin response to exogenous EPO, and reduce adipocyte expansion without altering osteoclast numbers.
• We expect that pharmacologic blockade of the leptin receptor (using a pegylated leptin antagonist) will mimic the genetic SOCS3 loss, lowering SOCS3 expression and improving EPO responsiveness.
• Inhibiting osteoclastogenesis (with anti-RANKL or os inhibitors) will lower marrow inflammation but won't rescue EPO-STAT5 signaling if SOCS3 remains intact, indicating that adipocyte leptin-SOCS3 is downstream of osteoclast activity.

Experimental approach

1. We'll harvest femoral marrow from young (3 mo) and aged (20‑24 mo) mice. Sort Ter119+CD71+ progenitors by flow cytometry. Measure leptin receptor phosphorylation, SOCS3 mRNA (qPCR) and protein (Western blot), and basal versus EPO-stimulated (5 U/mL, 15 min) pSTAT5 levels.

• Quantify adipocyte area with Oil-Red-O staining and osteoclast number with TRAP histology on femoral sections.
• Generate Gata1-Cre;Socs3^fl/fl mice and compare EPO response (weekly injections of 250 U/kg EPO for 2 weeks) to littermate controls; monitor hemoglobin, reticulocyte count, and marrow cellularity.
• Treat aged wild-type mice with a leptin receptor antagonist (e.g., Allo-PEG-LepAnt) or vehicle; assess the same endpoints as in step 3.
• In parallel, treat aged mice with os or anti-RANKL antibody; evaluate whether osteoclast reduction alone changes SOCS3 expression or EPO-STAT5 signaling.
• Perform competitive repopulation assays using SOCS3-deficient versus WT erythroid progenitors to test whether myeloid bias is corrected.

Falsifiability If SOCS3 deletion doesn't increase EPO-induced pSTAT5 or hemoglobin despite confirmed loss of SOCS3, the hypothesis isn't supported. If leptin receptor blockade doesn't lower SOCS3 or improve EPO signaling, the leptin-SOCS3 link is questionable. Conversely, if osteoclast inhibition normalizes SOCS3 levels and rescues EPO responsiveness independently of adipocyte changes, the proposed feed-forward loop would need revision.

This framework links niche adiposity, osteoclast-mediated inflammation, and intracellular SOCS3 feedback to explain why erythroid progenitors become refractory to EPO in aging, offering a testable path to disentangle microenvironmental contributions from intrinsic HSC exhaustion.